Join us on Thursday, January 28^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from Adaptive Biotechnologies Corporation, Bristol-Myers Squibb Company, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Oncopeptides and Takeda Oncology.

Thursday, January 28, 2021
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

MODULE 1: Treatment Paradigm for Newly Diagnosed and Relapsed/Refractory (R/R) Multiple Myeloma (MM)

• Design, eligibility criteria and key efficacy and safety findings from the Phase III ENDURANCE (E1A11) trial evaluating KRd (carfilzomib, lenalidomide and dexamethasone) versus RVd (lenalidomide, bortezomib and dexamethasone) as initial therapy for newly diagnosed MM; current indications for the use of up-front carfilzomib
• Published research findings with daratumumab-containing front-line regimens for newly diagnosed MM and optimal incorporation into treatment algorithms
• Emerging results from Phase III studies evaluating elotuzumab and ixazomib as components of induction therapy; implications for research and current care
• Published research evaluating the correlation between minimal residual disease (MRD) negativity and long-term outcomes for patients with newly diagnosed MM undergoing active treatment; role of MRD assessment to inform decision-making
• Available efficacy and safety outcomes with and current indications, if any, for ixazomib as maintenance therapy
• Clinical, biologic and practical factors in the selection, sequencing and combining of carfilzomib, pomalidomide, daratumumab, elotuzumab and ixazomib for patients with R/R MM
• Published data leading to the recent FDA approval of isatuximab for R/R MM; optimal use in clinical practice and ongoing research
• Available data with and FDA-endorsed role of selinexor for R/R disease
• Design, eligibility criteria and efficacy and safety results from the Phase III BOSTON trial evaluating selinexor in combination with bortezomib/dexamethasone for patients with MM who have received 1 to 3 prior lines of therapy; clinical implications

MODULE 2: Novel Investigational Strategies for the Management of MM

• Design, eligibility criteria and available efficacy and safety results from the pivotal Phase II KarMMa trial evaluating idecabtagene vicleucel for R/R MM; clinical implications
• Safety and efficacy findings from the Phase Ib/II CARTITUDE-1 study leading to the FDA breakthrough therapy designation for JNJ-4528 for R/R disease
• Early data and ongoing clinical research evaluating other chimeric antigen receptor T-cell platforms (eg, orvacabtagene autoleucel, bb21217) in MM
• Efficacy and safety results from studies evaluating belantamab mafodotin alone (DREAMM-2) or in combination with bortezomib/dexamethasone (DREAMM-6) in R/R MM
• FDA Oncologic Drugs Advisory Committee vote for positive benefit-risk profile for belantamab mafodotin; potential clinical role
• Available data with novel anti-BCMA bispecific T-cell engagers (BiTEs; eg, AMG 420, CC-93269, teclistamab) for MM
• Favorable risk-benefit ratio with venetoclax-based therapy for patients with t(11;14) or Bcl-2 overexpression; current nonresearch role, if any
• Published efficacy and safety data with and ongoing Phase III evaluation of melflufen for patients with multiple regimen-refractory MM
• Activity and safety observed with next-generation immunomodulatory agents in patients with heavily pretreated MM; ongoing evaluation and potential therapeutic role
• Other novel strategies in clinical development for MM

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Customize induction and subsequent maintenance therapeutic approaches for individuals with multiple myeloma (MM) eligible or ineligible for stem cell transplant, considering recently presented clinical trial findings and patient- and disease-related factors, including cytogenetic profile.
• Discuss available research data informing the use of monoclonal antibody therapy directed at CD38 as a component of induction therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into the clinical management of this disease.
• Evaluate research data with the use of minimal residual disease (MRD) status to predict long-term outcomes with therapy, and apply this information to determine the current and potential role of MRD testing in the protocol and nonresearch management of MM.
• Develop an understanding of the mechanism of action of and pivotal clinical trial findings with selinexor for previously treated MM, and identify patients for whom treatment with this novel compound is appropriate.
• Recognize the available research data leading to the FDA approval of isatuximab in combination with pomalidomide/dexamethasone for relapsed/refractory (R/R) MM, and discern how this agent should be effectively integrated into clinical algorithms.
• Recall the biologic rationale for targeting B-cell maturation antigen (BCMA) with novel therapies in MM, and recognize the similarities and differences among various investigational products.
• Appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapies directed at BCMA, and identify patients with R/R MM for whom this approach may be appropriate as part of a clinical research study.
• Understand the mechanism of action of and pivotal clinical trial findings with belantamab mafodotin for previously treated MM in preparation for the potential availability of this novel compound.
• Assess the mechanisms of action, available data and ongoing clinical trials with other novel, investigational approaches for MM, and counsel appropriately selected patients about participation in research protocols.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Fonseca — Advisory Committee: Adaptive Biotechnologies Corporation, ONCOtracker Inc; Consulting Agreements: AbbVie Inc, Aduro Biotech, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Merck, Novartis, ONCOtracker Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Oncology. Dr Kaufman — Consulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Tecnofarma; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Fortis Therapeutics, Janssen Biotech Inc, Sutro Biopharma; Data and Safety Monitoring Board/Committee: TG Therapeutics Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Adaptive Biotechnologies Corporation, Bristol-Myers Squibb Company, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Oncopeptides and Takeda Oncology.